Last update 21 Jun 2024
Birociclib
Last update 21 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms XZP 3287, XZP-3287, XZP3287 |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Structure
Molecular FormulaC27H36N8O5 |
InChIKeyNHANOMFABJQAAH-UHFFFAOYSA-N |
CAS Registry1374639-75-4 |
Related
12
Clinical Trials associated with Birociclib[14C]吡罗西尼在中国男性健康受试者体内的物质平衡与生物转化研究
[Translation] Study on the substance balance and biotransformation of [14C]birocilide in healthy Chinese male subjects
the Material Balance and Biotransformation Study of [14C] XZP-3287 in Healthy Chinese Male Subjects
吡罗西尼片（XZP-3287）联合来曲唑/阿那曲唑对比安慰剂联合来曲唑/阿那曲唑治疗HR阳性、HER2阴性晚期乳腺癌的多中心、随机、对照、双盲、III期临床研究
[Translation] A multicenter, randomized, controlled, double-blind, phase III clinical study of piroximate tablets (XZP-3287) combined with letrozole/anastrozole versus placebo combined with letrozole/anastrozole in the treatment of HR-positive, HER2-negative advanced breast cancer
100 Clinical Results associated with Birociclib
Login to view more data
100 Translational Medicine associated with Birociclib
Login to view more data
100 Patents (Medical) associated with Birociclib
Login to view more data
100 Deals associated with Birociclib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hormone receptor positive HER2 negative breast cancer | NDA/BLA | CN | 30 Aug 2023 | |
| Advanced breast cancer | Phase 3 | CN | 16 Nov 2021 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 27 Apr 2018 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 27 Apr 2018 | |
| Prostatic Cancer | IND Approval | CN | 28 Jun 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04539496 (ASCO2023) Manual  | Phase 2 | Hormone receptor positive HER2 negative breast cancer HR Positive | HER2 Negative | 131 | ollitpjptl(zxazhsdyas) = uiffndhvsc tjhipduzuc (oooeqzqvmp, 16.0 - 31.1) View more | Positive | 31 May 2023 | |
(subgroups with visceral disease) | ollitpjptl(zxazhsdyas) = cmbwjjptkn tjhipduzuc (oooeqzqvmp, 13.6 - 29.5) View more | ||||||
Phase 1 | 16 | oqhvdcbono(cqqjmlezet) = hnewbkzmxo vkqafffsbs (brhbjrgivf ) View more | - | 29 Sep 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free